TheEdgeResearch
Home / Stocks / QLI

Qilian International Holding Group Limited (QLI)

NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$5.41 ▼ -3.57%
Market Cap
$38.7M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
1.41
52-Wk Range
1.7755-6.69
CEO
Chen Xin
Country
CN
Currency
USD

Qilian International Holding Group Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Jiuquan, CN. The stock last traded at $5.41, down 3.57% on the session, giving a market capitalisation of $38.7M. On trailing twelve-month figures it carries a trailing P/E of -24.59, a net margin of -16.7%. Its beta of 1.41 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-24.59
Price / Sales
0.83
Price / Book
4.52
EV / EBITDA
-24.93
Gross margin
1.3%
Operating margin
-5.6%
Net margin
-16.7%
Return on equity
Debt / equity
0.01
Current ratio
5.18
Dividend yield
0.0%
Payout ratio
-23.0%
Company profile
Exchange
NASDAQ Global Market
Employees
298
IPO date
2021-01-12
Headquarters
Jiuquan, CN
About Qilian International Holding Group Limited

Qilian International Holding Group Limited (QLI), founded in 2019 and headquartered in Jiuquan, People's Republic of China, focuses on the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMDs), and a variety of other products. The company's diverse offerings include licorice-derived products such as Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, supplied to pharmaceutical companies for manufacturing traditional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient for producing compound licorice oral solutions. QLI also produces Qilian Shan oxytetracycline tablets, used to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and humans, alongside Qilian Shan oxytetracycline APIs for other pharmaceutical manufacturers. Its TCMD line features Ahan antibacterial paste, designed for addressing stubborn chronic skin ailments. Furthermore, the company provides heparin sodium preparations to pharmaceutical firms for developing medications related to cardiovascular diseases, cerebrovascular conditions, and hemodialysis. Beyond the medical sector, Qilian International offers Zhu Xiaochang natural sausage casings for culinary applications. In agriculture, it produces Xiongguan organic fertilizers, formulated to improve crop yield, enhance soil chemical properties, and reduce compaction, as well as Xiongguan organic-inorganic compound fertilizers to stimulate plant growth.

Comparable companies

Qilian International Holding Group Limited is most often compared with the following Healthcare names:

BNKKCERCEYENHEXOLUMOORKAPSTIRADSHLTSTSA
More research on QLI
QLI technical analysis QLI TheEdge Score Compare against peers
Open full interactive analysis & DCF →